Errata
Article Figures & Tables
Tables
- Table 2—
Baseline and posttreatment nerve function test values
Parameter Placebo Fidarestat Difference (95% CI) P† MNCV in median n 95 86 Baseline (m/s) 51.4 ± 0.5 51.8 ± 0.4 End of treatment (m/s) 51.2 ± 0.5 51.8 ± 0.4 Difference (m/s) −0.2 ± 0.4 −0.0 ± 0.4 0.2 (−0.8 to 1.2) 0.74 95% CI (−0.9 to 0.5) (−0.8 to 0.7) P* 0.55 0.90 F wave minimum latency in median n 96 88 Baseline (ms) 31.3 ± 0.3 31.3 ± 0.3 End of treatment (ms) 31.6 ± 0.3 30.8 ± 0.3 Difference (ms) 0.3 ± 0.2 −0.5 ± 0.2 0.8 (−1.2 to −0.3) <0.001 95% CI (−0.1 to 0.6) (−0.8 to −0.2) P* 0.11 <0.01 FCV in median n 96 88 Baseline (m/s) 56.7 ± 0.4 56.7 ± 0.5 End of treatment (m/s) 56.1 ± 0.4 57.6 ± 0.5 Difference (m/s) −0.6 ± 0.3 0.9 ± 0.3 1.6 (0.8 to 2.4) <0.001 95% CI (−1.2 to −0.1) (0.3 to 1.5) P* <0.05 <0.01 MNCV in tibial n 95 81 Baseline (m/s) 40.2 ± 0.5 40.1 ± 0.4 End of treatment (m/s) 40.3 ± 0.5 40.8 ± 0.4 Difference (m/s) 0.1 ± 0.4 0.8 ± 0.3 0.7 (−0.3 to 1.6) 0.15 95% CI (−0.6 to 0.8) (0.2 to 1.3) P* 0.81 <0.01 F wave minimum latency in tibial n 99 86 Baseline (ms) 54.8 ± 0.5 56.0 ± 0.6 End of treatment (ms) 54.4 ± 0.6 55.1 ± 0.6 Difference (ms) −0.4 ± 0.3 −0.9 ± 0.3 −0.5 (−1.3 to 0.4) 0.31 95% CI (−1.0 to 0.2) (−1.5 to −0.2) P* 0.21 <0.05 FCV in tibial n 99 86 Baseline (m/s) 47.7 ± 0.4 47.0 ± 0.5 End of treatment (m/s) 48.1 ± 0.5 47.6 ± 0.5 Difference (m/s) 0.4 ± 0.3 0.6 ± 0.3 0.2 (−0.6 to 1.0) 0.63 95% CI (−0.2 to 1.0) (0.1 to 1.1) P* 0.19 <0.05 SNCV in median (distal) n 82 67 Baseline (m/s) 47.8 ± 0.8 48.5 ± 0.9 End of treatment (m/s) 47.6 ± 0.9 48.8 ± 0.8 Difference (m/s) −0.1 ± 0.5 0.3 ± 0.5 0.4 (−1.0 to 1.9) 0.55 95% CI (−1.2 to 0.9) (−0.7 to 1.3) P* 0.81 0.54 SNCV in median (forearm) n 86 76 Baseline (m/s) 57.4 ± 0.6 57.0 ± 0.7 End of treatment (m/s) 57.4 ± 0.6 57.6 ± 0.6 Difference (m/s) −0.0 ± 0.5 0.6 ± 0.5 0.6 (−0.8 to 2.0) 0.37 95% CI (−1.1 to 1.0) (−0.3 to 1.5) P* 0.93 0.21
In this Issue
February 2002, 25(2)
